Society of Interventional Oncology: Research Grant Opportunities
This Society of Interventional Oncology (SIO) Grant is designed to fund research initiatives that:
- Evaluate immune stimulation of interventional oncologic therapies,
- Combine approaches to improve clinical outcome, and
- Improve the understanding of underlying mechanisms as to how different therapies influence both adaptive and innate immunity, as well as underlying inflammation and tumorigenesis.
New funding opportunity:
The Society of Interventional Oncology (SIO), working in collaboration with Guerbet, LLC, are accepting research proposals on the topic of transarterial lipiodol chemoembolization.
This collaboration establishes an independent research fund, generously sponsored by Guerbet, LLC that will enable SIO to offer grant funding for a wide array of research evaluating and advancing this premier interventional oncologic therapy.
Grant funding of up to $50,000 for one-year exploratory pilot projects and up to $100,000 for larger one to two-year projects with preliminary data.
All applications must be submitted electronically through our online application portal by Friday, June 1, 2018. Click here to learn more about the opportunity.
SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program:
The Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, and BTG plc (LSE: BTG), a global healthcare company focused on Interventional Medicine, announce their 2018 Interventional Oncology/Immuno-Oncology research grant recipients.
The investigators and project proposals that have been awarded grants are:
Rony Avritscher
University of Texas MD Anderson Cancer Center
Strategies to Modulate Liver Tumor Immune Microenvironment after Catheter-based Drug Delivery
Terence Gade, University of Pennsylvania
University of Pennsylvania
Characterization of the Immunobiologic Response Following Transarterial Chemoembolization of HCC
Samdeep Mouli
Northwestern University
Y90 Radioembolization Combined with Immune Checkpoint Blockade in an Animal Model of Hepatocellular
Isabel Newton
University of California, San Diego
Effects of Cryoablation on Hepatocellular Carcinoma Cancer Stem Cells and the Immune Response
Paul Thevenot
Ochsner Health System
Tumor-Induced Tolerance in Driving Embolization Resistance and Waitlist/Transplant Outcomes
